Month: March 2023

FY 2022 Net Sales and Adjusted EBITDA1 Exceed Previously Provided GuidanceFY 2023 Guidance Demonstrates Continued Strong Momentum on Top and Bottom Line LOUISVILLE, Colo., March 08, 2023 (GLOBE NEWSWIRE) — Sovos Brands, Inc. (“Sovos Brands” or the “Company”) (Nasdaq: SOVO), one of the fastest-growing food companies of scale in the United States, today reported financial results for its fourth quarter and fiscal year ended December 31, 2022. Fourth Quarter Highlights:Net sales were $262.1 million, a 38.5% increase over the prior year period, or 28.4% organic growth, driven by 16.0% volume and 12.4% pricing growth. The extra week in the Fourth Quarter 2022 compared to the prior year period contributed $19.1 million or 10.1% to growth2 Rao’s net sales for the quarter were $187.7 million, up 56.0% year-over-year or 44.6% on an organic...

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2022. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. “The significant progress we achieved in the fourth quarter sets up 2023 to be a potentially transformational year for TRACON,” said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. “In December we announced interim efficacy results from the ongoing ENVASARC pivotal trial demonstrating that envafolimab achieved a...

Zotatifin continued to demonstrate favorable activity and tolerability, including two previously reported confirmed partial responses (PRs) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A) Enrollment in expanded ECBF+A cohort completed and data is anticipated in first half of 2023 Topline data for Phase 2b KICKSTART trial in NSCLC anticipated in second half of 2023 Cash runway anticipated into first quarter of 2024 SOLANA BEACH and REDWOOD CITY, Calif., March 08, 2023 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update. “2022 was an important...

Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year Full Year Net Income Increases to $109.6 Million, Non-GAAP Adjusted EBITDA Increases to $101.6 Million Cash Flows from Operations Was $26.7 Million for the Fourth Quarter and $78.6 Million for the Full Year LAKE FOREST, Ill., March 08, 2023 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today reported financial results for the fourth quarter and full year ended December 31, 2022. Financial Highlights (unaudited):  Three Months Ended December 31,   Twelve Months Ended December 31,(in millions, except per share amounts)   2022       2021       2022       2021  Net Product Sales (GAAP) $ 49.9     $ 32.2     $ 155.1     $ 109.4  Net...

Q4 revenue of $19.7 million, down 3% year-over-year and up 30% quarter-over-quarter Q4 gross profit increased 1% year-over-year to $12.5 million as gross margins increased from 61% to 63% Generated $10.7 million in cash flow from operations in 2022 Repurchased 1.2 million shares during 2022 at an average price of $16.49 per share Exited 2022 with six Real-World Data Artificial Intelligence (RWD-AI) dealsROCHESTER, Mich., March 08, 2023 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the fourth quarter and full year ended December 31, 2022.  Twelve Months EndedDecember 31,Key Performance Indicators (KPIs)*   2022       2021  Average revenue per top 20 pharmaceutical manufacturer $ 2,143,296     $ 2,484,557  Percent...

Significantly Improved Quarterly Operating Profit and Net Income Growth Fourth quarter Gross Profit expands 130 basis points, Operating Income increases 152% 2022 Full Year Net Income of $6.5 million, a 68% increase from the prior year Continued deleveraging, with $11 million of full year debt repayments PRINCETON JUNCTION, N.J., March 08, 2023 (GLOBE NEWSWIRE) — MISTRAS Group, Inc. (MG: NYSE), a leading “one source” multinational provider of integrated technology-enabled asset protection solutions, reported financial results for its fourth quarter and year ended December 31, 2022. Highlights of the Fourth Quarter 2022*Revenue of $168.2 million, met the mid-point of management’s most recent guidance Gross profit of $50.9 million, with gross profit margin of 30.3%, a 130 basis points increase Income from Operations...

TN-201 IND Cleared in January; Plan to Begin Phase 1b Dosing in MYBPC3-associated HCM Patients in Third Quarter 2023 Dosing Commenced in Multiple-Ascending Dose Stage of First-In-Human Clinical Trial of TN-301; Data Anticipated in Second Half 2023 2022 Year End Cash and Investments of $204 Million; Runway to Fund Operations into First Half 2025 SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update. “Tenaya enters 2023 well capitalized and with meaningful milestones ahead,” said Faraz...